To determine whether the peripheral blood in humans contains a population of multipotent progenitor cells (MPCs), products of leukapheresis were obtained from healthy donor volunteers following the administration of granulocyte colony-stimulating factor. Small clusters of adherent proliferating cells were collected, and these cells continued to divide up to 40 population doublings without reaching replicative senescence and growth arrest. MPCs were positive for the transcription factors Nanog, Oct3/4, Sox2, c-Myc, and Klf4 and expressed several antigens characteristic of mesenchymal stem cells. However, they were negative for markers of hematopoietic stem/progenitor cells and bone marrow cell lineages. MPCs had a cloning efficiency of Ϸ3%, and following their expansion, retained a highly immature phenotype. Under permissive culture conditions, MPCs differentiated into neurons, glial cells, hepatocytes, cardiomyocytes, endothelial cells, and osteoblasts. Moreover, the gene expression profile of MPCs partially overlapped with that of neural and embryonic stem cells, further demonstrating their primitive, uncommitted phenotype. Following subcutaneous transplantation in nonimmunosuppressed mice, MPCs migrated to distant organs and integrated structurally and functionally within the new tissue, acquiring the identity of resident parenchymal cells. In conclusion, undifferentiated cells with properties of embryonic stem cells can be isolated and expanded from human peripheral blood after granulocyte colony-stimulating factor administration. This cell pool may constitute a unique source of autologous cells with critical clinical import.
T he recognition that the peripheral blood (PB) in adult humans may contain a population of multipotent progenitor cells (MPCs) would have relevant clinical implications for the treatment of multiple diseases in several organs. 1 This possibility would facilitate the acquisition and expansion of this cell pool and their subsequent delivery. To be effective clinically, MPCs should have the ability to engraft, grow, and differentiate in cell lineages specific of the damaged tissue and eventually lead to a structural and functional recovery of the injured organ. 2 Whether this undifferentiated cell pool is found in all individuals or is restricted to a subset of patients is as critical as the characterization of their phenotypic properties. Additionally, the gene expression profile and growth behavior of circulating MPCs must be compared with the properties of resident progenitor cells from solid and nonsolid organs such as the bone marrow, heart, and liver. 3, 4 This information is critical to determine whether they constitute an independent cell class or possess features of tissuespecific stem cells that migrated from the organ of origin to the circulation.
Two populations of progenitor cells, both named colonyforming units fibroblastic cells, have previously been identified in human PB 5, 6 : fibrocytes and mesenchymal stromal cells (MSCs). Fibrocytes are immunophenotypically similar to monocytes, grow modestly in culture and show a long population doubling time. 5 Conversely, MSCs display the morphology and surface phenotype of bone marrow resident mesenchymal cells and, occasionally, can be expanded in vitro. 6 Although fibrocytes may generate ectodermal, mesodermal, and endodermal structures, 7 the differentiation potential of MSCs has been restricted to the mesoderm. 8 The limitation in growth of fibrocytes and the lineage restriction of MSCs strengthens the need for identification of a circulating MPC that combines the plasticity of fibrocytes with the growth of bone marrow MSCs. This is relevant for the heart because there is no documentation yet that MSCs in mammals acquire the cardiomyocyte lineage in vitro or in vivo.
An essential premise of this putative human MPC must involve its ability to migrate to distant organs in an animal model, home to the tissue, survive in the unfamiliar milieu, differentiate, and ultimately acquire the function of resident parenchymal cells. If this were to be successful, this category of human MPCs may promote tissue repair and restore the structural and physiological integrity of the damaged organ.
Materials and Methods

Samples
Human specimens were collected in accordance with the Declaration of Helsinki and with approval by the Independent Ethics Committee of the University of Udine. Bone marrow samples (nϭ20) were obtained by iliac crest aspiration. For stem cell donors, granulocyte colony-stimulating factor (GCSF) mobilization regimen consisted of injections of 10 g/kg GCSF for 4 to 5 consecutive days. Leukapheresis (nϭ32) was performed on day 5 using an automated cell separator. Buffy coats (nϭ50), derived from nonmobilized healthy donors and destined to be discarded, were collected.
MPC and MSC Expansion
Mononuclear cells were isolated through density gradient centrifugation (Biocoll, Biochrom) (see the expanded Materials and Methods section in the online data supplement, available at http://circres. ahajournals.org). Bone marrow multipotent adult stem cells (MASCs) were obtained as described previously. 4 Online Table I in the online data supplement illustrates MPC and MSC culture conditions. Proliferating MPCs were subcultured. 4
Cytofluorimetric Analysis, Fluorescence Activated Cell-Sorting and Cloning
Cultured cells and mechanically disaggregated spleen cells were stained using directly conjugated primary antibodies and analyzed by a flow cytometer (CyAn, Beckman-Coulter). To generate singlecell-derived clones, a cell sorter (MoFlo, Beckman-Coulter) was used to automatically deposit individual cells in each well of 96-well Terasaki plates (nϭ1200 wells).
Telomere Repeat Amplification Protocol
Telomerase activity was detected with the TRAPeze kit (Chemicon).
Multilineage Differentiation In Vitro
Polyclonal (nϭ3) and clonogenic MPCs (nϭ39) were cultured in specific media 4 to induce their differentiation into osteoblast hepatocytes, endothelial cells, muscle cells, and neuronal cells. In all cases, cells were fixed and lineage commitment was determined by histological analysis, immunolabeling, and confocal microscopy (Online Table II ). Additionally, aliquots of differentiated cells were used for functional assays. The supernatant of cells cultured in hepatocyte and neural differentiation media were collected.
Microarray and RT-PCR Analysis
Total RNA was extracted using TRIzol and treated with DNase I. RNA was reverse-transcribed, and cDNA was amplified using the appropriate primers (Online Table III ). Microarray analysis was performed as described previously. 4
In Vivo Administration of MPCs
Undifferentiated MPCs at passage 3 were harvested resuspended in PBS at a final concentration of 4ϫ10 3 cells per microliter. Adult BALB-C mice (nϭ6, Harlan) were injected subcutaneously with 10 6 MPCs suspended in PBS, and the mice were euthanized 2 weeks later. Lungs, liver, spleen, heart, brain, bone marrow, femur, skeletal muscles, and the subcutis in proximity of the injection site were collected. Tissues were fixed in formalin or snap-frozen for immunolabeling and immunohistochemical studies, respectively (Online Table II ).
Statistical Analysis
Results are expressed as meansϮSD. Statistical significance was determined by unpaired Student's t test; PϽ0.05 was considered significant.
Experimental protocols are described in detail in the online data supplement.
Results
Isolation and Growth of Human MPCs
This study included 102 healthy volunteers divided in 3 groups: bone marrow (nϭ20), blood (nϭ50), and hematopoietic stem cell (nϭ32) donors. In the latter case, stem cell mobilization was induced by GCSF administration, and 1 mL of product of leukapheresis was obtained from each individual to isolate MPCs. Bone marrow samples were used to collect MASCs, which differentiate in endodermal, mesodermal, and ectodermal cell lineages. 4 These cells were used for comparison with MPCs. PB, in the absence of stem cell mobilization, was used to culture fibrocytes and MSCs. Therefore, the objective was to compare the growth behavior of MASCs, 4 fibrocytes, 5 MSCs, 6 and putative MPCs.
MASCs were consistently obtained in all 20 bone marrow samples ( Figure 1A ). Fibrocytes from PB were easily cultured but, as repeatedly shown, 5, 7, 8 Figure I ). We were unable to isolate MSCs from 50 samples of 50 mL each of human PB. Although 6 different growth media were tested (Online Table  I ), MSCs were not identified or failed to survive and expand under these conditions. This negative result questions the significance of this cell class for the colonization of the bone by circulating progenitors in humans. 6 Age may be a critical determinant of the pool size of MSCs in the blood, 9 possibly accounting for the difficulty to compare findings from different laboratories.
A complex procedure had to be implemented to isolate from 1 mL of product of leukapheresis an adherent fibroblastlike cell population (see Online Materials and Methods), which grew rapidly and retained an undifferentiated phenotype at serial passages (Figure 2A and 2B). Positive results were obtained in 5 cases, most likely because of the limited amount of product of leukapheresis available for analysis. At most, 2 to 3 clusters of adherent proliferating cells were acquired from each sample, documenting that the quantity at hand represented a critical determinant of the successful collection and growth of MPCs. In these positive examples, however, primitive cells continued to divide up to 40 population doublings without reaching replicative senescence and growth arrest. MPCs had a population doubling time of 38Ϯ3 hours, which was significantly shorter than that of MASCs (48Ϯ2 hours; PϽ0.0001).
In primary culture and after 3 and 20 population doublings, MPCs were positive for transcription factors typical of human embryonic stem (ES) cells, Nanog, Oct3/4, Sox2, c-Myc, and Klf4 ( Figure 2C through 2E). MPCs manifested high levels of telomerase activity, which exceeded that present in MASCs ( Figure 2F ). Telomerase activity was not detected in fibro-cytes. Additionally, fibrocytes were negative for the pluripotency markers, Nanog, Oct3/4, Sox2, c-Myc, and Klf4 (Figure 2C) . By FACS analysis, several antigens characteristic of mesenchymal stem cells were identified in MPCs. They included CD90, CD29, CD13, CD105, CD44, and CD73 (Online Figure II) . MPCs were negative for markers of hematopoietic stem/progenitor cells, including CD45, CD34, CD38, CD117, and CD133 and bone marrow cell epitopes such as CD14 ( Figure 2G ), CD4, CD8, CD19, and CD20 (data not shown).
MPCs Are Clonogenic and Multipotent
Stem cells possess 3 fundamental characteristics; they are self-renewing, clonogenic, and multipotent in vitro and in vivo. 10 To strengthen the notion that MPCs represented a stem cell class, individual MPCs were FACS sorted and automatically deposited in single wells of Terasaki plates. 11 Wells containing Ͼ1 cell were excluded from the analysis. Over a period of 2 to 3 weeks, 90 single-cell-derived multicellular clones were obtained from a total of 1200 deposited cells. The number of cells per clone varied from 100 to 500 ( Figure 3A ). Of the 90 clones, 39 were expandable, whereas 51 reached rapidly growth arrest. Therefore, MPCs had an actual cloning efficiency of Ϸ3%, which was significantly higher than that commonly found with resident progenitor cells from solid organs. 11, 12 Conversely, this value was lower than that obtained with mesenchymal cells from the bone marrow, heart, and liver. 4 Clonogenic MPCs were grown and characterized; they continued to express Nanog and Oct3/4 and displayed surface antigens essentially identical to those of MPCs in primary culture ( Figure 3B and Online Figure III) . Thus, during serial expansion, MPCs retained their original identity and immature phenotype, indicating that stem cells can be mobilized into the PB and collected and amplified in vitro in a selective manner.
To establish the differentiation potential of clonogenic MPCs, cells from single clones were exposed to neurogenic, myogenic, osteogenic, endothelial cell (EC), and hepatocyteforming media, respectively. 4 In neurogenic medium, MPCs acquired neuron-like cell morphology and expressed synaptophysin, neuron-specific enolase, and ␤3-tubulin arranged in filaments and bundles ( Figure 3C through 3E) . A fraction of MPCs maintained a flattened morphology and stained for glial fibrillary acidic protein ( Figure 3F ). Functional competence of MPC-derived neurons was documented by spontaneous release of the neurotransmitter L-glutamate ( Figure 3G ).
When clonogenic MPCs were exposed to myogenic medium, cardiomyocytes were formed; they expressed ␣-sarcomeric actin and ␣-cardiac actinin ( Figure 4A and 4B) . The gap junction protein connexin 43 was detected at sites of cell-to-cell contact ( Figure 4A ), and ryanodine receptors were distributed between filaments of ␣-actinin ( Figure 4B ). Spontaneous intracellular calcium oscillations were recorded in the presence of the calcium indicator Fluo-4 (Online Movie I). The ability of MPCs to commit to other mesodermal cell lineages was shown by culturing these cells in osteogenic and EC-forming media. Differentiating cells expressed osteopontin and incorporated tetracycline in areas of active calcium deposition (Online Figure IV, A) . Following stimulation with vascular endothelial growth factor (VEGF), the majority of cells stained for von Willebrand factor and were able to uptake acetylated LDL ( Figure 4C and 4D) .
The endodermal potential of MPCs was tested using a medium specific for hepatocyte differentiation. MPCs progressively assumed a globular shape and stained positive for cytokeratins 8, 18, and 19 ( Figure 4E ). Developing hepatocytes accumulated glycogen, released albumin, and, in response to phenobarbital, upregulated the expression and activity of cytochrome-CYP2B6 ( Figure 4F and 4G and Online Figure IV 
Gene Expression Profile of MPCs
cDNA microarray technology was used to characterize global gene expression of MPCs. Subsequently, the transcriptional profile of MPCs was compared with that of PB fibrocytes, mononuclear blood cells, and tissue resident MASCs. Unsupervised hierarchical clustering analysis was performed on differentially expressed genes (see the expanded Materials and Methods section in the online data supplement). A cluster dendrogram revealed a clear separation between MPCs and MASCs, on the one hand, and fibrocytes and mononuclear blood cells, on the other ( Figure 6A ). Quantitatively, fibrocytes and mononuclear blood cells showed an almost identical transcriptional profile. However, significant differences were detected between these cell classes and MPCs and MASCs, raising questions about the undifferentiated, multipotent state of fibrocytes. 5, 7 Conversely, the similarity in gene expression of MPCs and MASCs appeared to reflect the clonogenicity and multipotentiality of these cell categories ( Figure 6B and Online Table IV ).
In comparison with fibrocytes and mononuclear blood cells, MPCs and MASCs showed 6560 differentially expressed genes (adjusted PϽ0.001). Gene ontology-based functional annotation and EASE analysis 13, 14 were used to detect the biological function of the listed genes. Multipotent cells were enriched in transcripts for extracellular matrix proteins and intracellular protein trafficking, whereas fibrocytes and mononuclear blood cells were characterized by the expression of genes implicated in RNA processing, immune response, antigen presentation, immunoglobulins, and major histocompatibility complex domains (Online Tables V and VI) .
MPCs and MASCs expressed a core of common genes, consistent with the stem cell properties of both cell types.
However, a set of differentially expressed genes was also identified. To establish the biological import of these findings, analysis of functional annotation was performed. 15 With respect to MASCs, genes characteristic of neural and ES cells were upregulated in MPCs (Online Figure VI) , suggesting that this cell pool possessed a more immature embryonic-like phenotype.
Behavior of MPCs In Vivo
To determine whether MPCs can enter the systemic circulation, migrate to distant organs, and acquire mesodermal, endodermal and ectodermal cell lineages, these cells were injected subcutaneously in nonimmunosuppressed mice, and the presence of human structures was evaluated 2 weeks later in the spleen, heart, liver, brain, and skin. Nonimmunosuppressed mice were chosen in view of the immunomodulatory properties of bone marrow mesenchymal cells. Humanspecific anti-mitochondria and anti-nuclear lamin A/C antibodies were used to identify human cells in treated mice. With the exception of the heart, human cells were found in all other organs examined. These cells were positive for the hematopoietic makers CD34 and CD45 and were located underneath the capsule of the spleen in close proximity of foci of murine hematopoiesis ( Figure 7A through 7F) . Collectively, they comprised 0.05% of the entire cell pool ( Figure 7G ). Clusters of developing human hepatocytes which expressed cytokeratin 7 were detected in the mouse liver ( Figure 7H through 7K) . Additionally, scattered human cells resembling neurons were seen in the brain ( Figure 8A through 8C); in the skin, vessels of human origin were restricted to the dermis (Figure 8D through 8G) . In all cases, fluorescence in situ hybridization for human X and Y chromosome, chromosome 17, and human HER2 gene was implemented to confirm the human origin of the structures generated by engraftment and commitment of MPCs.
Discussion
In the present study, we have identified a novel population of cells which circulate in the PB and have properties of stem cells: clonogenicity, self-renewal, and multipotentiality. MPCs manifest surface epitopes similar to those present in MSCs but display a much more immature phenotype with molecular and functional characteristics restricted to human ES cells. 16 MPCs express the pluripotent state-specific transcription factors, Oct3/4, Nanog, and Sox2 together with c-Myc and Klf4. Additionally, they show high levels of telomerase activity, proliferate intensively in vitro, and, under permissive culture conditions, form cells of the 3 germ layers. 17 Following transplantation in vivo, MPCs migrate to distant organ and integrate within the new parenchyma, acquiring the identity of resident cells structurally and functionally.
The membrane immunophenotype of MPCs favors their mesenchymal ancestry, which is consistent with the complexity to detect these cells in the PB. 8, 18 The relatively low yield of MPCs after GCSF mobilization obtained in our study may be attributable to the small samples available for cell collection, inherent resistance of primitive cells of mesenchymal origin to migrate out of the organ of residence, 19 or both. , and differentiate into smooth muscle cells that express smooth muscle actin (green) (C) and cardiomyocytes that are positive for ␣-sarcomeric actin (red) (D) and connexin 43 (green) (D). E, Commitment to the EC lineage is documented by the uptake of acetylated LDL (red). F and G, MPCs give rise to hepatocytes that express cytokeratins 8, 18, and 19 (green) (F) and accumulate glycogen (PAS staining, purple) (G).
However, the critical determinant of the difficulty encountered in the isolation of MPCs may relate to the protocol used for the mobilization of bone marrow cells. Although GCSF is relatively effective in mobilizing CD34 ϩ cells in the circulation, 20 this strategy has not been optimized for nonhematopoietic progenitors, which show an inverse relationship with the number of mobilized CD34 ϩ cells. 21 Age and disease of the donor may also affect the egress of cells from the bone marrow. 22 Importantly, it has recently been emphasized that selective recruitment of bone marrow cell subsets is largely dependent on the cytokines used to promote cell migration, 23 providing the basis for the limited number of positive samples obtained here. Unfortunately, the demographic and clinical characteristics of volunteer donors and patients were not available to us; therefore, we could not conclude that age, sex, and the clinical conditions did not influence the number of circulating progenitors and their successful collection.
The retention of progenitor cells in bone marrow niches is primarily dictated by the interaction between CXCR4 expressed on the surface of the primitive cells and the stromal cell-derived factor-1 ligand released by neighboring supporting cells. 24, 25 The mechanism by which GCSF favors the translocation of progenitors to PB involves the disruption of the stromal cell-derived factor-1/CXCR4 axis by reducing the expression of both receptor and ligand. 26 This process is achieved more effectively by CXCR4 antagonists. With respect to GCSF, CXCR4 antagonists result in a more than 10-fold higher number of hematopoietic progenitors (HPCs) and endothelial progenitor cells in PB. However, GCSF alone or in combination with CXCR4 antagonists does not induce mobilization of a class of mesenchymal stem cells, 27 the stromal progenitor cells (SPCs). Conversely, the simultaneous administration of CXCR4 antagonists and VEGF suppresses migration of HPCs but favors the egress of SPCs from the bone marrow, although the number of SPC-derived colonies per milliliter of blood remains several orders of magnitude lower than that of effectively mobilized HPCs and endothelial progenitor cells. 27 These observations demonstrate that various subsets of bone marrow progenitor cells require the administration of different growth factors and reiterate the difficulty to disengage mesenchymal cells from their microenvironment. Optimal protocols for the mobilization of bone marrow cells into the PB remain to be developed. 23 The products of leukapheresis used in this work derived from GCSF treatment, which is the most effective protocol approved for bone marrow cell mobilization in patients. 28 However, mRNA levels for CXCR4 are significantly lower in MPCs than in the other circulating bone marrow cells examined here, weakening the mobilizing action of GCSF and preventing the use of CXCR4 antagonists. Similarly, MPCs do not possess VEGF receptor (VEGFR)2 and are, therefore, not responsive to VEGF. Careful analysis of the pattern of surface receptors present on MPCs may provide useful insights for optimizing MPC migration and harvesting. MPCs have relatively high levels of VEGFR1/flt1 that, on binding with placental growth factor, induces rapid chemotaxis of bone marrow repopulating and progenitor cells and attracts VEGFR1-positive cells at sites of tumor growth forming premetastatic niches. 29, 30 MPCs express IGFBP5, which in combination with insulin-like growth factor (IGF)-1 and IGF-2, promotes migration of undifferentiated mesenchymal cells. 31 However, MPCs possess a group of adhesion molecules including integrin ␣3, the integrin-related IT-GBL1, VCAM1, L1CAM, and OBCAM that may favor the retention of these cells in the bone marrow niches, further complicating their access to PB.
Although various hematopoietic and nonhematopoietic multipotent primitive cells have been recognized in human PB, 8, 18, 32 MPCs have unique characteristics in terms of growth, differentiation, and gene expression profile. At present, MPCs are the only circulating nonhematopoietic cells that form expandable clones composed of a homogenous pool of stem cells with broad differentiation potential. Because this 33 On injection in the blastocysts, induced-pluripotent stem cells display the ability to form ectodermal, mesodermal, and endodermal derivatives, together with germ cells. However, the efficiency of reprogramming is low underscoring the significance of the cell category identified in the present report; MPCs are a class of multipotent cells that are present in the PB and do not require retroviral gene transduction. The expression of pluripotent state-specific transcription factors has previously been detected in adult MSCs isolated directly from the bone marrow. 34 The transcriptional profile of MPCs differs markedly from that of fibrocytes and mononuclear blood cells but displays similarities with MASCs. The distinct molecular signature of these cell categories points to differential biological properties of each cell pool, which may have independent function in organ and organism homeostasis and repair. MASCs and MPCs have a superior and broader differentiation potential than MSCs. Importantly, adult MPCs may be ontologically related to ES cells; they share with ES cells multiple genes and behavioral phenotypes related to self-renewal, multipotentiality, and lineage specification. 35 In fact, MPCs are highly primitive cells that express pathways characteristically present in neural and ES cells. 36 MPCs and MASCs have a partially overlapping gene expression profile. However, the set of differentially expressed genes between these 2 cell classes includes highly immature markers that predominate in MPCs. This finding suggests that MPCs may represent the ancestors of MASCs in the hierarchy of bone marrow cells with mesenchymal surface immunophenotype.
The motile phenotype of circulating MPCs reflects their ability to migrate to distant tissues and successfully engraft and differentiate into the cell lineages of the recipient organ. Consistent with their remarkable cellular plasticity in vitro, MPCs can form ECs in the vessel wall, hepatocytes in the liver, and neurons in the brain. Additionally, the in vivo administration of MPCs unmasked their latent ability to integrate in sites of extramedullary hematopoiesis. The presence of clusters of CD45-positive CD34-positive human cells in the mouse spleen has raised 2 possibilities concerning the blood-forming potential of nonhematopoietic progenitors or the participation of MPCs in the "stem cell cycle." 37, 38 The latter may mirror a chronic oscillation from a quiescent mesenchymal-like state to an active hematopoietic phenotype.
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Figure 8.
MPCs engraft in the brain and accumulate at the site of injection. A through C, MPCs homed to the brain have the morphological characteristics of neurons. These cells are human in origin, as documented by human mitochondrial antigen (brown). D through G, Human MPCs are positive for the human mitochondrial antigen (brown) (D), human chromosome 17 (red) and HER2 (white) (E), and human X (red) and Y (green) chromosomes (F). G, Engrafted MPCs differentiate into ECs (CD31, green) in dermal vessels.
